Friday, 16 October 2026European Markets

ELIOR GROUP Stock Was Up By 10.41% On Thursday

Loading stream...

(vianews) - the market ended the session with elior group (elior.pa) rising 10.41% to €2.78 on thursday while cac 40 rose 0.59% to €7,575.85.

elior group's last close was €2.52, 39.89% under its 52-week high of €4.19.

about elior group

elior group sa offers contract catering and support services in france and internationally. the company provides contract catering services to business and industry, education, and healthcare sectors under the elior brand. it also offers a range of value-added services under the elior services brand, such as cleaning and hygiene services for hospitality, industrial premises, sales outlets, and agri-food industries; biological cleaning and hospitality services in the healthcare sector; and facility management services, including reception, mail management, minor maintenance, green areas, etc. the company operates approximately 20,250 restaurants and points of sale. elior group sa was founded in 1991 and is headquartered in paris, france.

earnings per share

as for profitability, elior group has a trailing twelve months eps of €-1.07.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -25.89%.

more news about elior group (elior.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com